Table 1 Patients' characteristics and post-COVID-19 symptoms.
Number of patients | 53 | |
Berlin | 18 | |
Cologne | 35 | |
Age (mean; range in years) | 45.1 | 24–71 |
Gender (n, %) | ||
Female | 33 | 62 |
Male | 20 | 38 |
Non-binary | 0 | 0 |
Course COVID-19 (n, %) | ||
Mild | 48 | 91 |
Moderate | 2 | 4 |
Severe | 3 | 6 |
Time between COVID-19 and blood sample (median, range in days) | 232 | 100–598 |
Time between COVID-19 and neuropsychological assessment (median, range in days) | 232 | 109–467 |
Time between neuropsychological assessment and blood sample (median, range in days) | 20 | 0–226 |
Symptoms (n, %) | ||
Cognitive complaints | 53 | 100 |
Fatigue | 40 | 75 |
Sleep disorder | 22 | 42 |
Depression | 18 | 34 |
Headache | 17 | 32 |
Myalgia | 12 | 23 |
Hyposmia/hypogeusia | 11 | 21 |
Vertigo | 8 | 15 |
Sensibility dysfunction | 4 | 8 |
Cranial MRI scans (n, %) | 43 | 81 |
Pathological findings | 8/43 | 19 |
MoCA | ||
Median, IQR | 27 | 25–29 |
< 26 (abnormal; n, %)) | 16 | 30 |
≥ 26 (normal; n, %) | 37 | 70 |
Neuropsychological assessment (n, %) | ||
Subjective cognitive decline | 16 | 30 |
Single-domain impairment | 16 | 30 |
Multi-domain impairment | 21 | 40 |
GFAP (pg/ml; median, IQR) | 89.7 | 67.0–107.6 |
NfL (pg/ml; median, IQR) | 7.4 | 6.0–10.0 |
